Study on the effect of skeletal muscle mass against side effects and hematological toxicity of chemotherapy

Relationship between skeletal muscle and amino acid blood levels and adverse events of anticancer drugs - Searching for the optimal dose of anticancer drug

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000048273

Enrollment

Registered

2022-07-05

Start date

2020-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer

Interventions

71days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients undergoing chemotherapy for esophageal cancer within the study period in gastrointestinal surgery. Regardless of age, gender, height or weight.

Exclusion criteria

Exclusion criteria: No particular exclusion criteria are set. Patients who are judged to be maladaptated by the judgment of physitian.

Design outcomes

Primary

Measure	Time frame
Frequency of hematological toxicity, degree of hematological toxicity, transition of iliopsoas muscle area, blood amino acid concentration, neutrophil elastase concentration, etc.	—

Countries

Japan

Contacts

Public ContactYuta Sato

Gifu University, School of Medicine Department of gastroenterological surgery and pediatric surgery

m03039ys@yahoo.co.jp058-230-6235

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026